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glioma
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Monocytes/macrophages have begun to emerge as key cellular modulators of brain homeostasis and central
nervous system (CNS) disease. In the healthy brain, resident microglia are the predominant macrophage cell
population; however, under conditions of blood-brain barrier leakage, peripheral monocytes/macrophages can
infiltrate the brain and participate in CNS disease pathogenesis. Distinguishing these two populations is often
challenging, owing to a paucity of universally accepted and reliable markers. To identify discriminatory marker sets
for microglia and peripheral monocytes/macrophages, we employed a large meta-analytic approach using five
published murine transcriptional datasets. Following hierarchical clustering, we filtered the top differentially
expressed genes (DEGs) through a brain cell type-specific sequencing database, which led to the identification of
eight microglia and eight peripheral monocyte/macrophage markers. We then validated their differential
expression, leveraging a published single cell RNA sequencing dataset and quantitative RT-PCR using freshly
isolated microglia and peripheral monocytes/macrophages from two different mouse strains. We further verified the
translation of these DEGs at the protein level. As top microglia DEGs, we identified P2ry12, Tmem119, Slc2a5 and
Fcrls, whereas Emilin2, Gda, Hp and Sell emerged as the best DEGs for identifying peripheral monocytes/
macrophages. Lastly, we evaluated their utility in discriminating monocyte/macrophage populations in the setting
of brain pathology (glioma), and found that these DEG sets distinguished glioma-associated microglia from
macrophages in both RCAS and GL261 mouse models of glioblastoma. Taken together, this unbiased bioinformatic
approach facilitated the discovery of a robust set of microglia and peripheral monocyte/macrophage expression
markers to discriminate these monocyte populations in both health and disease.
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Microglia represent the major population of myeloid
cells (monocytes) in the healthy brain parenchyma,
where they perform vital functions, ranging from
homeostatic surveillance to serving as the first line of
immune defense [45]. Microglia originate from primitive
macrophages that exit the yolk sac at mouse embryonic
day 8.5, and subsequently colonize the neuroepithelium
to become the resident CNS macrophage population
[34]. Under certain pathological conditions, peripheral
monocytes can enter the CNS from the blood through a
disrupted blood brain barrier [13]. While there is little
turnover of microglia in the healthy brain, blood mono-
cytes/macrophages exhibit a high turnover rate [46]. In
addition to their different origins, microglia and periph-
eral monocytes/macrophages have distinct functions in
the setting of brain pathology. For example, opposing ef-
fects of microglia and infiltrated monocytes/macro-
phages have been reported in malignant brain tumors
(glioblastoma) [5, 6, 9].
Defining the individual contributions of microglia
and infiltrated monocytes/macrophages has been ham-
pered by a lack of reliable markers that discriminate
these two macrophage populations. First, while mono-
cytes/macrophages are of haematopoetic origin, their
transcriptome substantially overlaps with microglial
gene expression [7, 16]. Second, some of the genes/pro-
teins used to distinguish these two populations are not ex-
clusively expressed by either microglia or macrophages,
but are only relatively enriched. This includes the protein
tyrosine phosphatase receptor type C (CD45), the fractalk-
ine receptor (CX3CR1), and the C-C chemokine receptor
type 2 (CCR2) [1, 4, 10, 15, 17, 25, 47]. Third, discrimin-
atory genes frequently employed to identify peripheral
monocytes/macrophages, such as CD45 or CCR2, can be
induced in microglia associated with brain tumors (gli-
oma). Similarly, blood-derived macrophages have been
reported to decrease their Ccr2 expression upon entry
into the brain under pathological conditions, while
these same conditions induce Ccr2 expression in
microglia [1, 4, 11, 32, 40, 47]. Lastly, while other
monocyte population-specific markers have been iden-
tified, including TMEM119, it is not clear that they
can reliably distinguish microglia from peripheral
monocytes/macrophages in the normal brain and in
the setting of CNS pathology [3, 5, 7, 14, 28].
In an effort to generate a resource for discriminating
microglia from peripheral monocyte/macrophage markers
in the normal brain and in the setting of disease, we
employed a meta-analytic approach using five published
mouse transcriptomal datasets, where profiles from both
microglia and peripheral monocyte/macrophage popula-
tions were included. In combination with several second-
ary selection filters and proteomic validation, a robust setof microglia and monocyte/macrophage DEGs was identi-
fied and shown to discriminate microglia from monocyte/
macrophages both in the normal brain and in the context
of experimental murine glioma.
Materials and methods
Animals and ethics statement
All mice used for quantitative RT-PCR or proteomics
validation were males, which were maintained on a
C57BL/6J genetic background. Animals were handled ac-
cording to governmental (LaGeSo) and internal (Max
Delbrück Center for Molecular Medicine) rules and reg-
ulations. For quantitative RT-PCR validation,
Cx3cr1EGFP/WT;Ccr2RFP/WT mice were used to isolate
microglia and peripheral monocyte/macrophages, re-
spectively. Mice were kept in the animal facility using
12 h of light and dark cycle, with food and water ad libi-
tum. All experiments were performed in strict accord-
ance with the German Animal Protection Law as
approved by the Regional Office for Health and Social
Services in Berlin (Landesamt für Gesundheit und
Soziales, Berlin, Germany, Permit Number (T0014/08,
O360/09, A-0376/17). Adult mice were euthanized by
intraperitoneal injection of pentobarbital (Narcoren,
Merial GmbH, Hallbergmoos, Germany). All efforts
were made to minimize pain and suffering.
Animals for the experimental glioma studies were
housed in the Cleveland Clinic Biological Resource Unit
or the Emory University Division of Animal Resources. All
experimental procedures were approved by the Institu-
tional Animal Care and Use Committee of the Cleveland
Clinic (Animal Protocol 2013–1029; approved June 25,
2013) and Emory University (Protocol #2003253; approved
September 15, 2015), and performed in strict accordance
with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of
Health. All surgeries were performed under anesthesia,
and all efforts were made to minimize suffering.
Experimental high-grade glioma mouse models
Ntv-a;Ink4a-Arf−/−;Gli-luc mice developed gliomas fol-
lowing intracranial RCAS-PDGFB injection by 6–8 weeks
of age. Tumors were subsequently collected at 10–13
weeks of age [20]. Mice of both sexes were used in these
experiments. Control mice were matched by genotype,
gender, and age and did not receive RCAS injections.
Fluorescence activated cell sorting (FACS) of microglia
and spleen monocytes/macrophages
12–14-week-old male C57/BL6 mice were transcardially
perfused under deep anesthesia with 1x Phosphate Buff-
ered Saline (PBS). Brains were isolated, and after re-
moval of the cerebellum and brainstem, dissociated into
a single-cell suspension using Adult Brain Dissociation
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gentleMACS dissociator (Miltenyi), according to manu-
facturer instructions. Subsequently, cells were washed in
PBS, passed through a 35 μm nylon mesh, counted and
stained with anti-Mouse CD11b + PE-Cyanine7 (Life
technologies | Thermo Fisher Scientific, Waltham,
Massachusetts, USA) and anti-Mouse CD45 eFluor 450
(Life technologies | Thermo Fisher Scientific) for 20mins
on ice. Spleens were manually dissociated in dissociation
buffer (PBS containing 5.6% Glucose and 15 mM Hepes),
and filtered through a 70 μm strainer and then passed
through a 35 μm nylon mesh. Subsequently, the resulting
single cell solution was centrifuged at 500 g for 5 min,
and red blood cells were lysed for 10 min in ACK buffer
at room temperature. PBS was added, samples centri-
fuged, and the supernatant was discarded prior to stain-
ing the cells with anti-Mouse CD11b+ PE-Cyanine7 (Life
technologies) and anti-Mouse CD45 eFluor 450 (Life
technologies), anti-Mouse Ly6G-FITC (eBioscience |
Thermo Fisher Scientific, Waltham, Massachusetts,
USA) and anti-Mouse Ly6C-PerCP/Cy5.5 (eBioscience |
Thermo Fisher Scientific) for 20mins on ice. After stain-
ing, cells were washed once in PBS, and sorted on a FACS
Aria flow cytometer (BD Biosciences, Franklin Lakes,
USA) according to the specified gating strategy: microglia
were sorted as CD11b+CD45low cells, whereas spleen
monocytes/macrophages were isolated as
CD11b+CD45highLy6GlowLy6Chigh cells. For brain and
spleen samples derived from Cx3cr1GFP/WT;Ccr2RFP/WT
mice, cells were collected after centrifugation, washed in
PBS, and the cell pellets snap frozen for storage at − 80 °C.Fluorescence activated cell sorting (FACS) of glioma-
associated microglia and monocytes/macrophages from
RCAS tumor mice
Whole brains were collected from anesthetized and Ringer’s
solution-perfused 3-month-old Ntv-a;Ink4a-Arf−/−;Gli-luc
female and male mice and stored overnight in cold media.
Tumors (n = 4), as well as age and gender matched fore-
brains from naïve animals (n = 4), were dissected and
dissociated. Microglia and monocytes/macrophages were
isolated using a Percoll density gradient for
antibody-mediated flow sorting [8]. Forward Scatter (FSC)
and Side Scatter (SSC) were used to determine viable cells,
and appropriate controls were included for compensation
and gating of stained populations (single, isotype and fluor-
escence minus one (FMO) controls) [2]. Two cell popula-
tions were collected from tumors: CD45high (infiltrated
monocytes/macrophages); CD45low (microglia) cells that
were also CD11b+, F11r+, Ly6Gneg, Sellneg, CD3neg,
CD19neg, and NK1.1neg cells. One population was collected
from normal brain: CD45low that was also CD11b+, F11r+,
Ly6Gneg, Sellneg, CD3neg, CD19neg, and NK1.1neg. FACSsamples were sorted directly into TRIzol (Life Technologies
Corporation, Carlsbad, CA) for total RNA extraction.
Gene expression analysis
Gene expression datasets were identified by specifically
choosing only studies that performed gene expression
analysis of both microglia and peripheral monocyte/
macrophage populations at the same time, in order to
minimize variation across sample preparation and analysis
between laboratories. Datasets used for the meta-analysis
included GSE46686 [33], GSE46690 [33], SRX424925 [22],
GSE48579 [7], and GSE86573 [5] (Table 1).
Microarray analysis
Raw data files were downloaded, and analyzed using R
package limma. The raw data was first normalized (RMA
normalization), and the two groups were contrasted (lmFit
and eBayes functions) in order to obtain the fold changes
and adjusted p-values between microglia and monocyte/
macrophage samples. The gene lists were further filtered
for significant differential expression between monocytes/
macrophages and microglia using a fold change (log2) cut-
off of 2 and an adjusted p-value cutoff of 0.01. Each
microarray dataset was individually analyzed.
RNA sequencing analysis
Processed data files were downloaded and analyzed
using different approaches depending on the dataset. For
normalized expression (fpkm) datasets, the values were
first log transformed, and the fold changes calculated
using limma (lmFit and eBayes function). For read
counts datasets, the fold changes were calculated by
DESeq2 package using default values. The gene lists
were further filtered for significant differentially
expressed genes between monocytes/macrophages and
microglia using a fold change (log2) cutoff of 2 and ad-
justed p-value cutoff of 0.01. Each RNA sequencing
dataset was individually analyzed.
Meta-analysis of mouse RNA sequencing and microarray data
In order to compare all datasets, gene IDs were con-
verted to gene symbols. Genes with increased expression
in microglia or monocytes/macrophages were compared
using the R package GeneOverlap to identify overlaps
and intersections. We only selected genes as potential
markers for each cell type that intersected in all of the
datasets. A heat map (heatmap.2 function) was then
constructed using the fold-change values (data were
scaled) for all of these markers, and adjusted according
to hierarchical clustering.
Analysis of mouse single-cell RNA sequencing (scRNA-Seq)
Single cell data from the Tabular Muris Consortium was
retrieved and analyzed [42]. All cells were labeled with
Table 1 Gene expression datasets used for the meta-analysis
Cell Type Dataset Tissue Species Platform Data Format Reference
microglia GSM1134004
GSM1134006
GSM1134009
GSM1134010
GSM1134012
GSM1134015
GSM1134055
GSM1134056
GSM1134057
brain mouse Aroma
Aroma
Aroma
Expression console
Expression console
Expression console
RNA-seq
RNA-seq
RNA-seq
CEL / microarray
CEL / microarray
CEL / microarray
CEL / microarray
CEL / microarray
CEL / microarray
Pong et al. 2013 [33]
peripheral monocytes/
macrophages
GSM1134005
GSM1134007
GSM1134008
GSM1134011
GSM1134013
GSM1134014
GSM1134052
GSM1134053
GSM1134054
Bone marrow mouse Aroma
Aroma
Aroma
Expression console
Expression console
Expression console
RNA-seq
RNA-seq
RNA-seq
CEL / microarray
CEL / microarray
CEL / microarray
CEL / microarray
CEL / microarray
CEL / microarray
Pong et al. 2013 [33]
microglia SRX424861
SRX424857
brain mouse RNA-seq
RNA-seq
Hickman et al. 2013 [22]
peripheral monocytes/
macrophages
SRX424925
SRX424919
SRX424904
SRX424890
SRX424880
SRX424879
SRX424878
peritoneum mouse RNA-seq
RNA-seq
RNA-seq
RNA-seq
RNA-seq
RNA-seq
RNA-seq
Hickman et al. 2013 [22]
microglia GSM1181585
GSM1181587
GSM1181589
brain mouse Affymetrix
Affymetrix
Affymetrix
CEL / microarray
CEL / microarray
CEL / microarray
Butovsky et al. 2014 [7]
peripheral monocytes/
macrophages
GSM1181579
GSM1181581
GSM1181583
spleen mouse Affymetrix
Affymetrix
Affymetrix
CEL / microarray
CEL / microarray
CEL / microarray
Butovsky et al. 2014 [7]
microglia GSM2590424
GSM2590425
GSM2590426
brain mouse RNA-seq
RNA-seq
RNA-seq
(Bowman et al. 2016 [5]
peripheral monocytes/
macrophages
GSM2590427
GSM2590428
GSM2590429
GSM2590430
GSM2590431
blood mouse RNA-seq
RNA-seq
RNA-seq
RNA-seq
RNA-seq
(Bowman et al. 2016 [5]
Haage et al. Acta Neuropathologica Communications            (2019) 7:20 Page 4 of 18the tissue of origin (brain myeloid cells or marrow) and
processed with Seurat software (v2.3). The two datasets
were normalized, scaled (data were regressed based on
ERCC spiked-in controls), and aligned together (CCA
dimension alignment). We generated t-SNEs from the
aligned CCA dimensions, and violin plots were created
to depict the expression of each of the markers on indi-
vidual cells from the two tissues.
Analysis of mouse RNA sequencing datasets from glioma-
associated microglia and glioma-associated monocytes/
macrophages
RNA sequencing datasets from high-grade glioma-
associated microglia and monocytes/macrophages iso-
lated from experimental RCAS or GL261 tumors were
extracted from GSE86573 or directly from the publishedmanuscript (Table 1) [5]. Log2 fold changes in
glioma-associated microglia relative to monocytes/mac-
rophages were calculated for all microglia signature
(SGMic) and monocyte/macrophage signature (SGMac)
genes, including conventionally used markers (Cx3cr1,
Cd11b, Cd45, Ccr2), and the data plotted accordingly.
Additionally, log2 fold changes in glioma-associated
microglia relative to healthy microglia were calculated
for all microglia signature (SGMic) genes and the data
plotted accordingly.
Quantitative RT-PCR validation
Total RNA was extracted from FACS-sorted acutely iso-
lated monocytes using ReliaPrep™ RNA Miniprep System
(Promega Corporation; Madison, Wisconsin, USA), and
first strand cDNA synthesis was performed using the
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Japan) according to the manufacturer’s instructions.
Quantitative real-time PCR reactions to amplify 1 ng of
total cDNA for the selected genes (Table 2) were per-
formed in a 7500 Fast Real-Time thermocycler (Applied
Biosystems, Carlsbad, USA) using the SYBR Select Master
Mix (Applied Biosystems | Thermo Fisher Scientific,
Waltham, Massachusetts, USA). CT values were normal-
ized using hypoxanthine guanine phosphoribosyltransfer-
ase (Hprt). To ensure the specificity of each PCR product,
melting curves were analyzed. The delta/delta CT-method
was employed for analysis of relative expression.
Protein extraction and mass spectrometry analysis
For each of the four independent proteomic runs, primary
monocyte populations from four different male C57BL/6J
mice were pooled and pelleted in PBS. The samples were
solubilized in Laemmli buffer (LB) and subjected to
SDS-PAGE. The proteome was focused into one gel band
and processed as previously published [26, 39], with the
use of an automated HTS PAL system (CTC Analytics,
Switzerland). Peptides were extracted, purified and stored
on reversed-phase (C18) StageTips [35]. Following
elution, the peptides were lyophilized and resus-
pended in 0.1% Formic Acid / 3% Acetonitrile, prior
to separation in a nano EasyLC 1200 (Thermo Fisher
Scientific) with a 0.1 × 200 mm MonoCap C18 High-
Resolution Ultra column (GL Sciences, Japan) at a
flow rate of 300 nL/min and a gradient from 5 to 95%
B (80% Acenotrile, 0,1% Formic Acid) in 360 min.
The UHPLC was coupled online to an Orbitrap QTable 2 Quantitative RT-PCR primers
Gene Forward Primer
C3 TGCCCCTTACCCCTTCATTC
Emilin2 GCAGCTTGTGGAACTGCATC
F10 GGTGAGTGAACCTTGCCCC
F5 CACCCGTGATACCTGCGAAT
Fcrls CTTGTGAGGCTGAAAACGCC
Gda GACAGCGGCAAAATAGTGTTT
Gpr34 CCTGGTCTAGGGAGTTTTGGG
Hp CACTTGGTTCGCTATCGCTG
Hprt GATTAGCGATGATGAACCAGG
Mki67 TGGTCACCATCAAGCGGAG
Olfml3 GCCGACTAGCTGCCTTAGAG
P2ry12 GCACGGACACTTTCCCGTAT
P2ry13 CCTCATCGCTTTCGACAGGT
Sell TCATGGTCACCGCATTCTCG
Siglec-H ATGTCAGCTGCCCTCATATCC
Slc2a5 ACAGCTGGCACTTTGAGGAG
Tmem119 CGGTCCTTCACCCAGAGCExactive plus mass spectrometer (Thermo Fisher Sci-
entific) for mass spectrometry analysis. The mass
spectrometer was set to acquire full-scan MS spectra
(300–1700m/z) at a resolution of 17.500 after accu-
mulation to an automated gain control (AGC) target
value of 1 × 106 and maximum injection time of 20
ms, and was operated in a data-dependent acquisition
mode, selecting the 10 most abundant ions for MS/
MS analysis, with dynamic exclusion enabled (20 s).
Charge state screening was enabled, and unassigned
charge states and single charged precursors excluded.
Ions were isolated using a quadrupole mass filter with
a 1.2 m/z isolation window, with a maximum injection
time of 60 ms. HCD fragmentation was performed at a
normalized collision energy (NCE) of 26. The recorded
spectra were searched against a mouse database from
Uniprot (January 2017) using the MaxQuant software
package (Version 1.5.2.8) [12] (with fixed modifications
set to carbamylation of cysteines and variable modifica-
tions set to methionine oxidation). Peptide tolerance was
20 ppm and the minimum ratio for LFQ was set to 2. The
false-discovery rate was set to 1% on protein and peptide
level. Statistical analysis of the data set was performed
using R-statistical software package (version 3.4.1), Prod-
igy (v0.8.2) and Perseus software (version 1.6.0.7).
For the data analysis, proteins that were only identified
by site or were potential contaminants were excluded.
Only those proteins discovered in at least three
biological replicates were used for column-wise analysis
using a two-sample t-test and a Benjamini-Hodgberg-
based FDR < 0.05.Reverse Primer
CTCCAGCCGTAGGACATTGG
TCGGTTGCTTCTGAGGGTTC
TGGCACGTTCCCGGTTAATA
TCAGTGCGTTTGGTGAAGGT
GCCATTCACCAAACGCACTT
CT AGGCCTGGCATGAAGAACTC
GAGCAAAGCCAGCTGTCAAC
TCCATAGAGCCACCGATGAT
TT CCTCCCATCTCCTTCATGACA
AGGCAGCTGGATACGAATGT
CCTCCCTTTCAAGACGGTCC
GCCTTGAGTGTTTCTGTAGGGTA
GAACATCAGGGACCAGACGG
CTTCACGGGAGGACTTGACG
CCTGTACCACATCTGCCAGG
TTGCCAGAGCAAGGACCAAT
TCGCAAGTAGCAGCAGAGAC
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Total RNA from flow-sorted cells was isolated by
TRIzol-chloroform extraction. RNA samples were resus-
pended in Ambion Nuclease-free water (Life Technolo-
gies), snap frozen, and stored at -80 °C. Prior to RNA
sequencing, RNA was treated with TURBO DNA-free
kit (Invitrogen | Thermo Fisher Scientific, Waltham,
Massachusetts, USA) and assessed using the Agilent
Eukaryotic Total RNA 6000 and Quant-iT™ RNA assay
kit on a Qubit™ Fluorometer (Life Technologies). cDNA
was synthesized using the Ovation® RNA-Seq method, and
the Illumina paired-end LT indexing protocol used to con-
struct an Illumina library from 500 ng cDNA [19, 30].
Libraries were sequenced on an Illumina HiSeq,
and15-22Mbp per lane of 100 basepair paired-end reads
generated. RNA-Seq paired-end reads were processed
using the TopHat suite [44] with Cufflinks [36, 37]. A
fold-change and significance (< 0.05 False Discovery Rate,
FDR) for every gene was generated using cuffdiff [43].
Data and software availability
The previously unpublished datasets from glioma-
associated microglia and macrophages using the RCAS
model are now available on the NCBI Gene Expression
Omnibus (GEO Accession Series GSE65868).
Results and Discussion
Meta-analysis of gene expression datasets from microglia
and peripheral monocyte/macrophage populations
To identify a reliable set of markers that distinguishes
microglia from peripheral monocytes/macrophages, we
leveraged a series of published RNA sequencing and
microarray datasets from adult mouse brain microglia
and peripheral monocyte/macrophage populations iso-
lated from mouse bone marrow, blood, spleen and peri-
toneum. We only included studies that performed gene
expression analyses of both populations, in order to
minimize variations in the processing of the different
samples between laboratories and the RNA analysis plat-
forms [5, 7, 22, 33]. Isolation protocols for microglia var-
ied among the studies; however, microglia were
commonly isolated by fluorescence-activated cell sorting
(FACS) using CD11b and CD45 expression. We incorpo-
rated datasets of monocyte/macrophage populations
from different tissue origins, since there were few pub-
lished studies that performed simultaneous sequencing
of microglia and monocyte/macrophage populations.
As such, the selected datasets included RNA sequen-
cing and microarray data from brainstem microglia
(CD11b+CD45lowLy6G−) and bone marrow-derived
macrophages (CD11b+CD115+Ly6G−) isolated by
fluorescence-activated cell sorting [33], RNA sequen-
cing of microglia (CD11b+CD45+) and peritoneal
macrophages (CD11b+CD45+; [22]), microarray datafrom microglia (CD11b+CD45low) and spleen mono-
cytes (CD11b+Ly6C+; [7]), and RNA sequencing of
microglia (CD11b+CD45+Ly6G− Ly6C−) and blood
monocytes (CD11b+CD45+Ly6G− Ly6C+ [5]).
Since the microarray and RNA sequencing data were
analyzed using different methods and pipelines, we used
the difference of gene expression (fold changes) between
microglia and peripheral monocytes/macrophages within
each dataset. Log-fold change values of enriched genes
for each of the two populations were compared across
the five different datasets (Fig. 1a). We identified 143
genes in microglia relative to peripheral monocytes/mac-
rophages that were shared across the five analyzed stud-
ies. Next, hierarchical clustering was performed,
revealing 13 microglia-enriched genes, including St3gal6
(Type 2 lactosamine alpha-2,3-sialyltransferase), P2ry13
(P2Y purinoceptor 13), P2ry12 (P2Y purinoceptor 12),
Sparc (Secreted Protein Acidic And Cysteine Rich),
Slco2b1 (Solute carrier organic anion transporter family
member 2B1), Gpr34 (Probable G-protein coupled re-
ceptor 34), Slc2a5 (Solute carrier family 2, facilitated
glucose transporter member 5), Sall1 (Sal-like protein
1), Siglec-H (Sialic acid-binding Ig-like lectin H), Olfml3
(Olfactomedin-like protein 3), Tmem119 (Transmem-
brane protein 119), Hpgds (Hematopoietic prostaglandin
D synthase), and Fcrls (Fc receptor-like S, scavenger re-
ceptor) (Fig. 1b, left panel). For the monocyte/macro-
phage populations derived from bone marrow, blood,
spleen or peritoneum, 145 significantly enriched and
specific genes shared across all five datasets were identi-
fied. Following hierarchical clustering, two clusters were
selected, representing 14 genes with the highest ex-
pression differences relative to microglia, including
F10 (Coagulation factor X), Emilin2 (Elastin Micro-
fibril Interfacer 2), F5 (Coagulation factor V), Slpi
(Anti-leukoproteinase), Fn1 (Fibronectin), C3 (Com-
plement C3), Anxa2 (Annexin A2), Gda (Guanine
deaminase), Mki67 (proliferation marker protein
Ki-67), Cd24a (CD24a antigen), S100a6 (S100
Calcium Binding Protein A6), Mgst1 (Microsomal
glutathione S-transferase 1), Sell (L-selectin), and Hp
(Haptoglobin) (Fig. 1b, right panel).
In order to evaluate the specificity of the identified
markers for distinguishing microglia and monocytes/mac-
rophages in the brain, we next assessed their expression in
different CNS cell types using the Brain RNA-Seq tran-
scriptome and splicing database [48]. Expression values
were extracted for each gene within each marker set in
microglia/macrophages, neurons, astrocytes, oligodendro-
cyte precursor cells, newly formed oligodendrocytes, mye-
linating oligodendrocytes and endothelial cells (Fig. 1c).
For the set of microglia-enriched genes, we defined an ex-
pression threshold of 25 FPKM, such that any gene with a
FPKM greater than 25 in any given CNS cell type other
ab
c
Fig. 1 Meta-analysis of mouse gene expression datasets from microglia and peripheral monocyte/macrophage populations derived from bone
marrow, blood, spleen and peritoneum. (a) Venn diagram representing commonly expressed genes across the analyzed RNA sequencing and
microarray datasets for microglia (red) and peripheral monocytes/macrophages isolated from bone marrow, blood, spleen or peritoneum (blue).
Bioinformatic analysis of the five different expression studies identified 143 microglia-specific genes and 145 genes specific for peripheral
monocytes/macrophages. The number of microglia and peripheral monocyte/macrophage genes exclusively expressed in each of the datasets is
represented. (b) Heat map representing gene expression (Z-score) of the identified 143 microglia-specific and 145 peripheral monocyte/
macrophage-specific genes in each of the analyzed gene expression datasets. Hierarchical clustering identified modules of microglia-specific and
of peripheral monocyte/macrophage-specific genes based on the dendrogram. For microglia, the module with the highest differential gene
expression of identified microglia marker genes containing St3gal6, P2ry13, P2ry12, Sparc, Slco2b1, Gpr34, Slc2a5, Sall1, Siglec-H, Olfml3, Tmem119,
Hpgds and Fcrls was selected for further analysis. For peripheral monocytes/macrophages, the two modules with highest differential gene
expression containing the genes F10, Emilin2, F5, Slpi, Fn1, C3, Anxa2, Gda, Mki67, Cd24a, S100a6, Mgst1, Sell and Hp were selected for further
analysis. (c) Representation of the expression levels for each of the selected microglia- and peripheral monocyte/macrophage-specific genes in
different CNS cell types, including microglia/macrophages, neurons, astrocytes and oligodendrocyte precursor cells (OPCs), newly formed
oligodendrocytes, myelinating oligodendrocytes and endothelial cells. FPKM values were extracted from the online database Brain-RNA-Seq
(Zhang et al. 2014). The threshold FPKM expression value for excluding genes as microglia markers was set to 25, leading to elimination of
St3gal6, Sparc, Slco2b1, Sall1 and Hpgds as microglia markers for further validation. Threshold FPKM expression value for excluding genes as
peripheral monocyte/macrophage markers was set to 10, leading to elimination of Slpi, Fn1, Anxa2, Cd24a, S100a6 and Mgst1 as monocyte/
macrophage markers for further validation
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were eliminated from further analysis due to their high ex-
pression in endothelial cells, Sparc because of its high ex-
pression in all CNS cell types, and Sall1 and Hpgds due to
their low expression in microglia/macrophages. The 14
identified monocyte/macrophage markers exhibited low
expression levels in microglia [48], consistent with the no-
tion that there are few, if any, peripheral monocytes/mac-
rophages in the healthy brain. We defined 10 FPKM reads
as a threshold for the exclusion of monocyte/macrophage
markers due to their expression in other brain cell types.
For this reason, we eliminated Slpi due to its expression in
newly formed and myelinating oligodendrocytes, Fn1 and
Anxa2 due to their high expression in endothelial cells,
and Cd24a for its high expression in neurons and endo-
thelial cells. S100a6 and Mgst1 were also excluded, since
they were highly expressed in astrocytes, OPCs and oli-
godendrocytes, astrocytes and endothelial cells, respect-
ively. Taken together, a panel of eight specific microglia
signature genes (SGmic: P2ry13, P2ry12, Gpr34, Slc2a5,
Siglec-H, Olfml3, Tmem119, Fcrls) and eight specific
peripheral monocyte/macrophage signature genes
(SGmac: F10, Emilin2, F5, C3, Gda, Mki67, Sell, Hp)
were identified.
Since these analyses included monocyte/macrophage
populations derived from blood, bone marrow, spleen,
and peritoneum, we also analyzed the expression of the
identified SGmac genes across the different populations
as shown in Additional file 1: Figure S1. While all
markers were expressed in the different monocyte subsets,
Hp, Sell and Gda were highly expressed in blood mono-
cytes relative to spleen, bone marrow-derived or periton-
eal macrophages. In addition, peritoneal macrophages
exhibited high levels of Fn1, Slpi, Emilin2 and F10 expres-
sion, while Hp, Sell, Mgst1 and S100a6 were expressed at
lower levels. Bone marrow-derived monocytes showed
highest expression of Cd24a and Mki67, C3 and Fn1.
Validation of SGmic and SGmac in single-cell sequencing
datasets
To provide a second method for assessing the utility of
these monocyte marker sets in discriminating microglia
from peripheral monocytes/macrophages, we leveraged a
recently published study using single-cell sequencing of
microglia and bone marrow-derived cells [42]. For mye-
loid brain cells, data were collected from 4762 cells,
while for bone marrow cells, data were derived from
5353 single cells. The bone marrow-derived cells were
next sorted in silico for Cd11b and Cd45 to identify
monocytes; however, almost all of the cells expressed
these two markers, making discrimination impossible.
We next tried to sort for the fractalkine receptor
(Cx3cr1), since peripheral monocytes/macrophages ex-
press only low levels of Cx3cr1 [17, 24]. Unfortunately,Cx3cr1 was expressed in myeloid brain cells, precluding
its use to presort monocytes/macrophages from bone
marrow-derived cells in silico. Thus, we compared the
expression of the two marker sets in the brain myeloid
fraction (termed microglia; MG) with the bone marrow
cells (termed BM). Expression of each of the eight identi-
fied signature genes for microglia (Fig. 2a) and peripheral
monocytes/macrophages (Fig. 2b) was normalized, and in-
dependently represented for each of the two populations.
Of the eight SGmic genes, six (P2ry13, P2ry12, Gpr34,
Slc2a5, Olfml3, Tmem119) were present in the
single-cell sequencing data, and all were enriched in the
microglia population relative to the bone marrow-
derived cells. P2ry12, Olfml3 and Tmem119 were
enriched in nearly all of the sequenced cells, whereas
P2ry13, Slc2a5 and Gpr34 were enriched, but not exclu-
sively expressed in all of the sequenced microglia.
Siglec-H and Fcrls were not present in the single cell
RNA sequencing dataset. Conversely, all eight SGmac
genes (F10, Emilin2, F5, C3, Gda, Mki67, Sell, Hp) were
present in the bone marrow single cell sequencing data-
set [42]: Hp and C3 were enriched in the bone marrow
cells compared to microglia; however, C3 was also
expressed in a small microglia population at elevated
levels. All other monocyte/macrophage marker genes
were enriched in bone marrow-derived cells relative to
brain myeloid cells, with varying expression levels across
the sequenced single cells. Mki67 and Gda were
enriched at higher levels than Emilin2 and F5. Sell and
F10 expression was evenly distributed across the se-
quenced cells, with F10 showing comparatively lower ex-
pression levels. In addition, the t-SNE distribution of
microglia and bone marrow cells was examined, and the
expression of the eight identified signature genes plotted
for each of the populations as shown in Additional file 2:
Figure S2. The brain myeloid cells clustered homoge-
nously in the middle of the plot, and the expression of
the eight SGmic genes correlated with that cluster. In
contrast, the bone marrow cells formed six different
clusters distributed at the periphery of the microglia
cluster, of which, all of the SGmac genes were localized
to at least two of these clusters.
We also examined the expression of four canonical
microglia/macrophage markers (Cd11b, Cd45, Cx3cr1
and Ccr2) within the Tabula Muris dataset (Fig. 2c).
While Cd11b and Cd45 were expressed in both mye-
loid brain cells and bone marrow-derived cells,
Cx3cr1 was enriched in microglia. Expression of the
commonly used peripheral monocyte/macrophage
marker Ccr2 was only slightly enriched in the bone
marrow cells, with very low levels of expression.
Taken together, the classically used monocyte popula-
tion markers underperformed as discriminatory genes
relative to Tmem119, P2ry12, and Olfml3 as microglia
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Fig. 2 Validation of SGmic and SGmac gene expression in single-cell RNA sequencing datasets of brain myeloid cells (microglia) and bone
marrow cells. Graph depicts normalized expression of single cell sequencing data of brain myeloid cells (termed MG for microglia) and bone
marrow cells (BM) extracted from the Tabular Muris dataset [42] for (a) SGmic and (b) SGmac genes relative to the conventional markers Cd11b,
Cd45, Cx3cr1 and Ccr2 (c)
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monocyte/macrophage markers.
SGmic and SGmac genes discriminate freshly isolated
microglia from peripheral monocytes/macrophages
To determine the discriminatory capabilities of these
identified markers, we employed two different ap-
proaches. First, we isolated microglia as CD11b+CD45low
cells and spleen monocytes/macrophages as
CD11b+CD45highLy6GlowLy6Chigh from 12-week-old
male C57BL/6J mice by fluorescence-activated cell sort-
ing (FACS), and determined their relative expression by
RT-qPCR analysis (Fig. 3a). All eight SGmic markers
were enriched and exclusively expressed in microglia
relative to spleen monocytes/macrophages: Olfml3, Fcrls,
and Gpr34 exhibited the highest expression, with only
P2ry12 demonstrating very low expression levels in
spleen monocytes/macrophages as shown in Additional
file 3: Figure S3a. In addition, all eight SGmac markers
were enriched in spleen monocytes/macrophages relative
to microglia: F10, Emilin2, C3, Gda and Hp were exclu-
sively and highly expressed in spleen monocytes/macro-
phages, whereas F5, Mki67 and Sell were detected at low
levels in microglia (Additional file 3: Figure S3a).
Using a second complementary method, we examined
the SGmic and SGmac genes in Cx3cr1GFP/WT;Ccr2RFP/
WT mice, where green fluorescent protein (GFP) expres-
sion is driven by the fractalkine receptor (Cx3cr1) pro-
moter, revealing microglia in the healthy brain as GFP+
cells. Conversely, red fluorescent protein (RFP) expres-
sion is controlled by the Ccr2 promoter, allowing for the
identification of peripheral monocytes/macrophages as
RFP+ cells. While this mouse model was originally de-
signed to distinguish CNS resident microglia from per-
ipheral monocytes/macrophages, several studies have
identified low Cx3cr1 expression in the latter population
[17, 24, 25]. Consistent with this observation, we de-
tected a RFP+GFP+, as well as a RFP+GFP−, population
in the Cx3cr1GFP/WT;Ccr2RFP/WT spleen samples. Using
this strain, we isolated microglia (GFP+RFP− cells) from
the healthy brain and two populations of spleen mono-
cytes/macrophages (RFP+GFP+ and RFP+GFP− cells)
from 8 to 12-week-old male mice. We defined the
RFP+GFP+ cells as the spleen monocyte/macrophage
population (Fig. 3b).
Next, we determined the expression of the SGmic and
SGmac marker sets across the three populations, focus-
ing primarily on GFP+RFP− microglia and RFP+GFP+
spleen monocytes/macrophages. All eight SGmic genes
were enriched in the GFP+RFP− microglia population
relative to RFP+GFP+ cells, as well as to RFP+GFP− cells
(Fig. 3b; Additional file 3: Figure S3b). In these analyses,
Tmem119, Fcrls, Olfml3 and Slc2a5 exhibited the highest
levels of expression. As observed in C57BL/6J WT mice(Fig. 3a), low levels of P2ry12 expression were detected
in both spleen monocyte/macrophage populations
(Additional file 3: Figure S3b). Conversely, the eight
SGmac genes were enriched in the RFP+GFP+ popula-
tion relative to GFP+RFP− microglia, with Emilin2, Gda
and Hp showing the highest expression levels. Sell was the
only marker expressed at higher levels in the RFP+GFP−
population (Additional file 3: Figure S3b), but was still
enriched in both isolated spleen monocyte/macrophage
populations as compared to GFP+RFP− microglia.
Proteomic analysis confirms P2ry12, Tmem119, Slc2a5,
and Fcrls as microglia markers, and Gda, Hp, C3, Mki67
and Emilin2 as monocyte/macrophage markers
To provide a third line of evidence for the discrimin-
atory ability of the identified SGmic and SGmac gene
sets, we sought to confirm their differential expression
at the protein level. Proteomics data were generated
from microglia (CD11b+CD45low) and spleen mono-
cytes/macrophages (CD11b+CD45highLy6GlowLy6Chigh)
isolated by FACS from 12-week-old naïve C57BL/6J
male mice. Protein expression levels of the SGmic and
SGmac genes were calculated from the measured IBAQ
intensities and normalized to Gapdh (Fig. 4a), and the
t-test differences in protein expression determined
(Fig. 4b). Since P2ry13 and Gpr34 could not be identified
in the proteomic analysis, they were excluded. Enrich-
ment of P2ry12, Slc2a5, Olfml3, Tmem119, and Fcrls
protein levels were observed in microglia relative to
spleen monocytes/macrophages. When normalized to
Gapdh, P2ry12 expression was highest in microglia,
followed by Tmem119, Slc2a5 and Fcrls. Olfml3 protein
expression, however, was higher in spleen monocytes/
macrophages than in microglia. The switch in quantifi-
cation can be explained by the method of protein extrac-
tion for proteomic analysis. Since Olfml3 is a secreted
protein, only the intracellular amount of the protein can
be accurately recovered and quantified. When compared
to spleen monocytes/macrophages, P2ry12 showed the
highest t-test difference, followed by Tmem119, Slc2a5,
Fcrls and Olfml3.
The monocyte/macrophage markers F5 and F10 could
not be detected in the proteomics analysis, which might
be explained by the fact that both are secreted proteins
and intracellular protein levels might fall below prote-
omic detection levels. Normalized to Gapdh, Gda and
Hp showed the highest protein expression levels in per-
ipheral monocytes/macrophages, followed by C3, Mki67
and Sell. For Gda and Hp, very low protein expression
in microglia was observed. Relative to microglia, C3,
Mki67, Gda and Hp protein levels showed the highest
t-test difference, followed by Emilin2 and Sell. As a ref-
erence, protein expression of the conventionally used
microglia/macrophage markers, Cx3cr1, Cd11b, Cd45
ab
Fig. 3 (See legend on next page.)
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Fig. 3 Validation of SGmic and SGmac genes by quantitative RT-PCR analysis in microglia and spleen monocytes/macrophages freshly isolated
from two different mouse models. (a) Microglia and spleen monocytes/macrophages were freshly isolated from 12-weeks old male C57BL/6J WT
mice by FACS. Microglia were first gated as CD11b+ cells against forward scatter (FSC) and subsequently selected as CD45low expressing cells
(microglia; red; CD11b + CD45low). Spleen monocytes/macrophages were first gated based on CD11b+ and CD45high expression, followed by
gating for Ly6Glow and Ly6Chigh expression (spleen monocytes/macrophages; blue; CD11b + CD45low Ly6Glow Ly6Chigh). Expression of SGmic
(P2ry13, P2ry12, Gpr34, Slc2a5, Siglec-H, Olfml3, Tmem119, and Fcrls) and SGmac (F10, Emilin2, F5, C3, Gda, Mki67, Sell, Hp) genes was assessed in
microglia (CD11b+ CD45low) and spleen monocytes/macrophages (CD11b+ CD45high Ly6Glow Ly6Chigh) by quantitative RT-PCR. (b) Microglia and
spleen monocytes were freshly isolated from 8 to 12 weeks old male Cx3cr1GFP/WT; Ccr2RFP/WT mice by FACS. Microglia were gated as GFP-
expressing cells against FSC (microglia; red; GFP+RFP−). Spleen monocytes/macrophages were isolated as RFP-expressing cells and sorted as two
populations based on their GFP-expression levels as RFP+GFP+ (spleen monocytes/macrophages; blue) and RFP+GFP− cells (spleen monocytes/
macrophages; purple). Expression of SGmic (P2ry13, P2ry12, Gpr34, Slc2a5, Siglec-H, Olfml3, Tmem119, and Fcrls) and SGmac (F10, Emilin2, F5, C3,
Gda, Mki67, Sell, Hp) genes was assessed in microglia (GFP+RFP− cells) and spleen monocytes/macrophages (RFP+GFP+ cells) by quantitative
RT-PCR. Bar graphs represent the log fold change expression of each gene normalized to Hprt and in the isolated microglia population relative
to the peripheral monocytes/macrophage population (CD11b+ CD45high Ly6Glow Ly6Chigh or RFP+GFP+ cells; blue; n = 3)
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expressed in both microglia and spleen monocytes/mac-
rophages, Cx3cr1 was enriched in microglia, and Cd45
and Ccr2 were mildly enriched in peripheral spleen
monocytes/ macrophages when compared to microglia.
Taken together, we provide the first transcriptomic and
proteomic evidence for Hp, Gda, Sell, C3, Mki67 and
Emilin2 as specific markers for peripheral monocytes/
macrophages and P2ry12, Tmem119, Slc2a5 and Fcrls as
microglia-specific markers.
SGmic and SGmac genes discriminate between glioma-
associated microglia and monocytes/macrophages
Using the SGmic and SGmac gene sets, we next ex-
plored their utility for discriminating between microglia
and infiltrated monocytes/macrophages in the setting of
brain cancer. For these studies, we employed datasets
derived from two different experimental murine glio-
blastoma models, the induced RCAS-TVA system [20]
and the GL261 glioma explant system [38].
First, we generated RCAS/TVA-induced tumors in
Ntv-a;Ink4a-Arf−/−;Gli-luc mice by RCAS-mediated ex-
pression of PDGFB, and subsequently isolated
tumor-associated microglia and monocytes/macrophages
based on CD11b+, CD45low, F11r+, Ly6Gneg, Sellneg,
CD3neg, CD19neg, and NK1.1neg (microglia) and CD11b+,
CD45high, F11r+, Ly6Gneg, Sellneg, CD3neg, CD19neg, and
NK1.1neg (monocytes/macrophages) gating. RNA se-
quencing was performed, and the log2 fold changes in
expression were calculated for each gene (Fig. 5a). In the
RCAS/TVA system, all SGmic genes (P2ry13, P2ry12,
Gpr34, Slc2a5, Siglec-H, Olfml3, Tmem119, Fcrls) were
enriched in glioma-associated microglia relative to
glioma-associated monocytes/macrophages, with Slc2a5,
Siglec-H, Gpr34 and P2ry12 showing the highest differ-
ential expression. Similarly, the SGmac markers F10 and
Hp were increased in glioma-associated monocytes/mac-
rophages (log2-fold changes = 3–4.7), whereas Emilin2,
Gda and Sell were slightly increased (log2-fold changes
= 1.1–1.8) and C3 and Mki67 only barely enriched. F5
did not show any changes in gene expression between
glioma-associated microglia and monocytes/macro-
phages. The canonical reference genes, Cx3cr1, Cd11b
and Cd45 were all enriched in microglia, while the clas-
sical monocyte/macrophage marker Ccr2 was enriched
in monocytes/macrophages isolated from RCAS tumors.
As further confirmation, we leveraged an
independently-generated RNA sequencing dataset gener-
ated by the Joyce laboratory using the identical RCAS
platform [5]. In this study, glioma-associated microglia
were isolated from RCAS-induced gliomas based on
CD45+CD11b+Ly6G−Ly6C−TdTomato+GFP− expression,
whereas glioma-associated monocytes/macrophages were
isolated as CD45+CD11b+Ly6G−Ly6C−TdTomato−GFP+cells. Data were extracted, and the log2-fold change ex-
pression of glioma-associated microglia calculated relative
to glioma-associated monocytes/macrophages (Fig. 5b).
All eight SGmic genes were enriched in glioma-associated
microglia in this RCAS dataset, with Slc2a5, Siglec-H,
Gpr34 and P2ry12 exhibiting the highest expression,
followed by Tmem119, Fcrls, P2ry13 and Olfml3, similar
to the experimental data presented in Fig. 5a. The periph-
eral monocyte/macrophage marker genes F5, Gda, Hp,
Sell and F10 were strongly enriched in glioma-associated
monocytes/macrophages, followed by Emilin2. Mki67 ex-
pression did not show a significant difference between
glioma-associated microglia and monocytes/macrophages,
while C3 was slightly enriched in the glioma-associated
microglia fraction. Similarly, Cx3cr1 and Cd11b were only
slightly enriched in glioma-associated microglia, while
Cd45 and Ccr2 were enriched in glioma-associated mono-
cytes/macrophages.
We then employed a second published RNA sequen-
cing dataset derived from the GL261 glioma model sys-
tem that was also analyzed by the Joyce laboratory [5].
GL261 glioblastoma tumors were implanted in wild-type
C57BL/6J mice and glioma-associated microglia were
isolated as CD45+CD11b+Ly6G−Ly6C−TdTomato+ cells
by FACS sorting, while glioma-associated monocytes/
macrophages were isolated as CD45+CD11b+Ly6-
G−Ly6C− TdTomato− cells. As above, we calculated
log2-fold changes in gene expression (Fig. 5c), and found
that all eight identified microglia and peripheral mono-
cyte/macrophage markers were significantly enriched in
the glioma-associated microglia and monocyte/macro-
phage populations, respectively. Similar to the
RCAS-TVA tumors, Slc2a5 and Siglec-H were expressed
at the highest levels in GL261 glioma-associated micro-
glia, followed by P2ry12 and Gpr34, while F10, Emilin2,
Gda, Sell and Hp showed the highest expression in
glioma-associated monocytes/macrophages. As previ-
ously seen, C3 and Mki67 were only barely enriched in
glioma-associated monocytes/macrophages. While
Cd11b was enriched in GL261-derived monocytes/mac-
rophages, the other classical monocyte marker genes
(Cx3cr1, Cd45 and Ccr2) showed enrichment in
GL261-derived microglia.
In addition, we assessed whether and how the patho-
logic condition of glioma affects SGmic gene expression
in microglia by calculating the log2 fold changes of
SGmic gene expression between glioma-associated
microglia and healthy microglia in both glioma models
and for all three RNA sequencing datasets as shown in
Additional file 4: Figure S4. All SGmic genes showed a
decrease in their expression levels in glioma-associated
microglia as compared to healthy microglia across gli-
oma models and datasets (log2-fold changes = 0.05-5.0),
except for Fcrls in the RCAS dataset published by
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Fig. 5 Expression of SGmic and SGmac genes in glioma-associated microglia and monocytes/macrophages isolated from two different experimental
mouse glioma models. (a) RCAS tumors were generated by injection of RCAS-PDFGB into Ntv-a;Ink4a-Arf−/−;Gli-luc mice, and after 5 weeks, glioma-
associated microglia were isolated as CD11b+, CD45low, F11r+, Ly6Gneg, Sellneg, CD3neg, CD19neg, NK1.1neg cells, while glioma-associated monocytes/
macrophages were isolated as CD11b+, CD45high, F11r+, Ly6Gneg, Sellneg, CD3neg, CD19neg, NK1.1neg cells by FACS. Graph shows RNA sequencing
results of the two populations as log2-fold change expression of glioma-associated microglia to monocytes/macrophages for SGmic (P2ry13, P2ry12,
Gpr34, Slc2a5, Siglec-H, Olfml3, Tmem119, Fcrls) and SGmac (F10, Emilin, F5, C3, Gda, Mki67, Sell and Hp) genes, as well as the reference genes (Cx3cr1,
CD11b, CD45, Ccr2). Genes not detected in the previous proteomic analysis (see Fig. 4; SGmic: P2ry13, Gpr34 and SGmac: F10, F5) are colored with
gradients. Graphs show log2-fold change expression of the SGmic and SGmac genes in glioma-associated microglia versus monocytes/macrophages
isolated from (b) RCAS and (c) GL261 tumors derived from published sequencing data [5]. Glioma-associated microglia were isolated from RCAS
tumors based on CD45+CD11b+Ly6G−Ly6C− TdTomato+ GFP− expression, glioma-associated monocytes/macrophages were isolated as
CD45+CD11b+Ly6G−Ly6C− TdTomato− GFP+ cells. GL261 glioma-associated microglia were isolated as CD45+CD11b+Ly6G−Ly6C−TdTomato+ cells and
glioma-associated monocytes/macrophages were isolated as CD45+CD11b+Ly6G−Ly6C− TdTomato− cells
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strongest decrease across datasets, while Olfml3 and
Tmem119 expression was least affected (Slc2a5 = − 0.68
to − 5.0; P2ry12 = − 0.61 to − 1.89; Olfml3 = − 0.05 to −
1.17; Tmem119 = − 0.50 to − 1.99).
The value of the SGmic and SGmac markers for
understanding CNS pathogenesis
Myeloid cells are highly dynamic cells whose transcrip-
tomes are highly influenced by specific disease states,
limiting their utility as reliable and stable cell identity
markers. As such, microglia harbor gene expression pat-
terns that reflect specific neuropathological conditions
[21, 23]. For example, in experimental mouse models of
Alzheimer’s disease (AD) and amyotrophic lateral scler-
osis, unique microglia gene expression patterns have
been reported [11, 27, 29]. Moreover, even within the
same disease state (e.g., AD), microglia change their
transcriptomes during the evolution of the pathologic
process, reflecting the trajectory of cellular reprogram-
ming in response to neurodegeneration and other CNS
pathologies [31]. These temporal and spatial changes in
microglial gene expression, and likely function, in the
setting of CNS disease support the need for discrimin-
atory markers that distinguish resident microglia from
infiltrating monocyte/macrophage populations, so that
the relative contributions of each monocyte population
can be studied in greater detail.
The commonly used markers for distinguishing micro-
glia from infiltrated monocytes/macrophages in the
mouse system, including CD45, CX3CR1, and CCR2,
have limitations that reflect their relative expression
levels, which are presumed not to vary as a function of
cellular context. In this regard, CD45 expression is fre-
quently employed to distinguish microglia from periph-
eral monocytes/macrophages in FACS-based monocyte
cell separations. However, this distinction relies upon
gating the cells for differential expression levels, where
microglia express low to intermediate levels and
blood-derived monocytes/macrophages express high
levels [15]. Obtaining clean separations is therefore
dependent on the overlap between the different
CD45-expressing populations, and does not consider
that these levels could vary under pathological condi-
tions. Germane to this latter issue, glioma-associated
microglia increase CD45 expression in vivo, rendering
them indistinguishable from CD45high-expressing mono-
cytes/macrophages [32]. In addition, we found that Cd45
expression was enriched in glioma-associated microglia
relative to glioma-associated monocytes/macrophages
(Fig. 5a, c). Similarly, while Cx3cr1 is often considered to
be microglia-specific, circulating monocytes and resident
tissue macrophages can also express Cx3cr1. Additionally,
Ccr2, a blood-derived macrophage marker [16–18, 25],can be induced in microglia following lipopolysaccharide
(LPS) treatment or reduced in blood-derived monocytes/
macrophages once they enter the brain in the context of
CNS pathology [1, 4, 11, 40, 47]. This problem is further
underscored by the observation that Ccr2 was enriched in
glioma-associated monocytes/macrophages in both
RCAS-tumor datasets, while it was enriched in glioma-
associated microglia isolated from the GL261-tumors
(Fig. 5). Finally, we have previously shown that peripheral
monocytes/macrophages acquire expression of a
microglia-specific gene (F11r) upon entry into the brain
using an experimental model of graft versus host disease
and, rendering infiltrating monocytes/macrophages indis-
tinguishable from resident microglia [33].
Similarly, several studies postulated novel and exclu-
sive markers for identifying microglia in disorders affect-
ing the CNS, including Tmem119 [3] and P2ry12 [7]. As
such, TGF-ßR1, Fcrls, Gpr34, Sall1 and P2ry12 [7], as
well as Siglec-H [28], have been reported to be expressed
at higher levels in microglia than in peripheral mono-
cytes/macrophages. CD49D/Itga4 has also been de-
scribed as a specific marker for bone-marrow derived
macrophages due to its transcriptional suppression in
microglia, and has been shown to separate the two cell
populations in murine and human tumors [5]. In
addition, TREM2 has similarly been suggested to distin-
guish infiltrated monocytes/macrophages from microglia
[14]. However, none of these markers has been accepted
as a universal standard.
The lack of a common set of markers to distinguish
microglia from peripheral monocytes/macrophages that
infiltrate the CNS has limited our understanding of the
relative contributions of each of these monocyte popula-
tions to neurologic disease pathogenesis. In the present
study, we employed an unbiased and comprehensive
meta-analytic approach, combined with numerous ex-
perimental validations to identify two sets of highly reli-
able markers for microglia (SGmic) and peripheral
monocytes/macrophages (SGmac). These SGmic and
SGmac gene sets were then leveraged to separate micro-
glia from infiltrating monocytes/macrophages in two dif-
ferent experimental mouse models of high-grade glioma.
Within these marker sets, P2ry12, Tmem119, Slc2a5 and
Fcrls performed best to discriminate microglia from
other cell types, while Emilin2, Gda, Hp and Sell were
the best markers for peripheral monocytes/macrophages.
Throughout all investigated conditions and approaches,
these markers were more reliable and performed better
than the commonly used microglia/macrophage discrim-
inators, underscoring their utility for discriminating
these myeloid cell populations in both health and glioma
and arguing for their use in future studies. Despite the
observation that SGmic gene expression changed in
glioma-associated microglia, and that LPS exposure
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Olfml3 [3], the SGmic genes still outperformed the com-
monly used discriminators.
Based on the ability of our prime candidate microglia
signature genes (P2ry12, Slc2a5, Tmem119 and Fcrls), as
well as our top candidate marker genes for peripheral
monocytes/macrophages (Gda and Hp, Sell and Emi-
lin2), to stably distinguish these two populations in the
normal brain, and in the context of high-grade glioma, it
is interesting to note that a preliminary analysis indicates
that P2ry12, Slc2a5 and Tmem119 genes are expressed
in glioma-associated microglia isolated from a murine
low-grade glioma model [41]. Thus, besides further
proving the validity of SGmic and SGmac genes as reli-
able markers used in the field of glioma research, their
applicability might also be explored in the broader con-
text of other CNS diseases.
While Tmem119 and P2ry12 have already been shown
to reliably identify human healthy microglia [3, 7], our re-
sults suggest that the other SGmic genes (P2ry13, Gpr34,
Slc2a5, Siglec-H, Olfml3, Fcrls) may also serve as human
microglia markers. Moreover, future studies might explore
whether Tmem119, P2ry12 (and potentially other SGmic
genes) might possess the ability to distinguish glioma-
associated microglia from glioma-associated monocytes/
macrophages in human glioma tissue.
Since the SGmic genes (P2ry12, Slc2a5, Tmem119 and
Fcrls) and SGmac genes (Gda and Hp, Sell and Emilin2)
were validated at the protein level and are predicted to
be expressed at the plasma membrane, it becomes pos-
sible to consider them for future protein-based applica-
tions, such as Western blotting, immunocytochemistry,
FACS analysis, and potentially for generating new mouse
reporter or Cre driver lines.
Conclusions
Using large meta-analytic approach, we identified a robust
panel of microglia and peripheral monocyte/macrophage
markers, which were independently validated at the RNA
and protein levels. The value of these discriminating
marker sets was further explored in the setting of glioma,
where they distinguished glioma-associated microglia
from macrophages in two mouse glioblastoma models.
Future studies employing these discriminatory genes/pro-
teins to separate monocyte populations may facilitate the
discovery of novel and distinct functions for microglia and
infiltrating monocytes/macrophages in CNS disease.
Additional files
Additional file 1: Figure S1.. Expression levels of selected differentially
expressed macrophage marker genes after hierarchical clustering in
peripheral monocyte/macrophage subpopulations isolated from blood,
spleen, peritoneum and bone marrow. (a) The differentially-expressedSGmac genes, which were identified in cluster 1 (Cd24, Mki67, Gda, Anxa2,
C3, Fn1, Slpi, Emilin2, F10) following hierarchical clustering of the 145
significantly enriched and specific peripheral monocyte/macrophage
genes shared across all five datasets, are shown. Expression is shown as
the log2 fold change of expression of the peripheral monocyte/
macrophage subpopulations isolated from blood (dark green; [5]),
spleen (light green; [7]), peritoneum (light blue; [22]) and bone
marrow (dark grey; [33]) compared to microglia for each of the
datasets. For bone marrow-derived monocyte/macrophages, the
RNA-sequencing dataset from Pong et al. is shown [33]. (b) The
differentially-expressed SGmac genes, which were identified in cluster
2 (Hp, Sell, Mgst1 and S100a6) following hierarchical clustering of the
145 significantly enriched and specific peripheral monocyte/macrophage
genes shared across all five datasets, are shown. Expression is shown as the
log2 fold change of expression of the peripheral monocyte/macrophage
subpopulations isolated from blood (dark green; [5]), spleen (light green;
[7]), peritoneum (light blue; [22]) and bone marrow (dark grey; [33])
compared to microglia for each of the datasets. For bone marrow- derived
monocyte/macrophages, the RNA-sequencing dataset from Pong et al. is
shown [33]. (PDF 393 kb)
Additional file 2: Figure S2. Spatial visualization, clustering and
expression of SGmic, SGmac and classical monocyte/macrophage marker
genes in single cell sequencing data derived from brain myeloid and
bone marrow cells. (a) t-distributed Stochastic Neighbor Embedding
(t-SNE) spatial visualization and clustering of brain myeloid single cells
(microglia; turquoise) dataset and bone marrow single cells (red) dataset
derived from the single cell sequencing data of the Tabula Muris
Consortium [42]. The right panel depicts clusters 1–16 represent all
different cell populations detected by automatic clustering (Seurat
FindCluster function). (b) t-SNEs showing the expression of the SGmic
genes within the spatial distribution of brain myeloid and bone marrow
cells. Identified SGmic genes from the analyzed single cell sequencing
dataset comprise P2ry13, P2ry12, Gpr34, Slc2a5, Olfml3, Tmem119. (c)
t-SNEs showing the expression of the SGmac genes (F10, Emilin2, F5, C3,
Gda, Mki67, Sell, Hp) within the spatial distribution of brain myeloid and
bone marrow cells. (d) t-SNEs showing the expression of the canonical
monocyte/macrophage markers (Cx3Cr1, Cd11b, Cd45 and Ccr2) within the
spatial distribution of brain myeloid and bone marrow cells. (PDF 14645 kb)
Additional file 3: Figure S3. Validation of SGmic and SGmac genes in
microglia and peripheral monocytes/macrophages freshly isolated from
two different mouse models. (a) Microglia (CD11b+ CD45low; red) and
circulating spleen monocytes (CD11b+ CD45high Ly6Glow Ly6Chigh; blue)
were freshly isolated from 12-week-old male C57/Bl6 WT mice by FACS
and the expression of SGmic genes (P2ry13, P2ry12, Gpr34, Slc2a5, Siglech,
Olfml3, Tmem119, and Fcrls; red) and SGmac genes (F10, Emilin2, F5, C3,
Gda, Mki67, Sell, Hp; blue) determined by quantitative RT-PCR. Bar graphs
represent the fold change expression of marker genes normalized to Hprt,
where SGmic genes (red) are shown in relation to the spleen monocyte/
macrophage population (CD11b+ CD45high Ly6Glow Ly6Chigh; blue) and
SGmac genes (blue) compared to microglia (n = 3). For statistical analysis,
unpaired t-tests were performed. * = P < 0.05; ** = P < 0.01; *** = P < 0.001.
(b) Microglia and spleen monocytes/macrophages were freshly isolated
from 8 to 12-week-old male Cx3cr1GFP/WT;Ccr2RFP/WT mice by FACS,
GFP+RFP− cells representing microglia (red), RFP+GFP+ (blue) and RFP+GFP−
(purple) cells representing spleen monocytes/macrophages. The expression
of SGmic genes (P2ry13, P2ry12, Gpr34, Slc2a5, Siglech, Olfml3, Tmem119, and
Fcrls; red) and SGmac genes (F10, Emilin2, F5, C3, Gda, Mki67, Sell, Hp; blue)
was determined by quantitative RT-PCR. Bar graphs represent the fold
change expression of each gene normalized to Hprt, where SGmic
genes (red) are shown in relation to spleen monocytes/macrophages
(RFP+GFP+; blue) and SGmac genes compared to microglia
(GFP+RFP− cells; n = 3). For statistical analysis, one-way ANOVA
following Bonferroni’s multiple comparison test was performed.
* = P < 0.05; ** = P < 0.01; *** = P < 0.001. (PDF 401 kb)
Additional file 4: Figure S4. Expression of SGmic genes in glioma-
associated microglia as compared to healthy microglia in RNA
sequencing datasets derived from healthy, RCAS glioma or GL261 glioma
mice. (a) The log-fold change expression of SGmic genes (P2ry13, P2ry12,
Gpr34, Slc2a5, Siglec-H, Olfml3, Tmem119, Fcrls) in glioma-associated
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isolated from healthy control brains is shown. Expression data were
extracted from RNA sequencing data generated by our group. (b) The
log-fold change expression of SGmic genes (P2ry13, P2ry12, Gpr34, Slc2a5,
Siglec-H, Olfml3, Tmem119, Fcrls) in glioma-associated microglia isolated
from RCAS tumors compared to microglia isolated from healthy control
brains is shown. Expression data were extracted from published RNA
sequencing data [5]. (c) Graph shows the log-fold change expression of
SGmic genes (P2ry13, P2ry12, Gpr34, Slc2a5, Siglec-H, Olfml3, Tmem119, Fcrls)
in glioma-associated microglia isolated from GL261 tumors as compared to
microglia isolated from healthy control brains. Expression data were
extracted from published RNA sequencing data [5]. (PDF 394 kb)
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Fig. 1 The threshold FPKM expression value for excluding genes as microglia markers is 70 (panel c)
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Fig. 3 Bar graphs represent the log10 fold change expression (panel a and b)
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Fig. 5 Bar graphs represent the log10 fold change expression (panel a, b and c)
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